Holen Sie sich die Stockscreener-App
15.00
0.99%
-0.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.15
Offen:
$15.29
24-Stunden-Volumen:
1.24M
Relative Volume:
1.08
Marktkapitalisierung:
$682.05M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-18.07
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-5.96%
1M Leistung:
+6.69%
6M Leistung:
+227.51%
1J Leistung:
+288.60%
1-Tages-Spanne:
$14.75
$15.58
1-Wochen-Bereich:
$14.28
$16.46
52-Wochen-Spanne:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
15.00 | 682.05M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell? - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2%Still a Buy? - MarketBeat
Capricor Therapeutics Inc (CAPR) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Examining the Potential Price Growth of Capricor Therapeutics Inc (CAPR) - Knox Daily
Capricor Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Capricor Therapeutics Announces Upcoming Participation in Key Investor Conferences for 2025 - Nasdaq
Capricor (CAPR) to Showcase DMD Breakthrough at Three Elite Healthcare Conferences - StockTitan
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.1%Should You Sell? - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by SG Americas Securities LLC - Defense World
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Gaining Ground: Capricor Therapeutics Inc (CAPR) Closes Lower at 14.33, Down -4.91 - The Dwinnex
BlackRock, Inc. Expands Stake in Capricor Therapeutics Inc - GuruFocus.com
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Exosome Diagnostics & Therapeutics Market to Grow by USD 1.01 Billion (2025-2029) with Rising Research in Exosome Therapeutics Boosting the Market, Report on How AI is Driving Market TransformationTechnavio - The Malaysian Reserve
Capricor Therapeutics Inc [CAPR] Stock bought by Insider Nippon Shinyaku Co Ltd for $15.0 million - Knox Daily
Ready to Jump After Recent Trade: Capricor Therapeutics Inc (CAPR) - SETE News
Capricor wins key EU designations for the lead asset - MSN
Capricor Therapeutics Inc (NASDAQ:CAPR) Decline -1.05%, More Rally Possible - Marketing Sentinel
How to Take Advantage of moves in (CAPR) - Stock Traders Daily
5 DMD Candidates to Watch in 2025 - BioSpace
JPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
JPMorgan Chase & Co. Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Equities Analysts Set Expectations for CAPR FY2025 Earnings - Defense World
Analysts Set Expectations for CAPR FY2025 Earnings - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Now Is The Time To Build A Position In Capricor Therapeutics Inc (NASDAQ:CAPR) - Marketing Sentinel
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capricor Therapeutics Inc-Aktie (CAPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):